Springer Nature
Browse
12895_2016_51_MOESM1_ESM.docx (238.9 kB)

Additional file 1: of Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial

Download (238.9 kB)
journal contribution
posted on 2016-10-03, 05:00 authored by Kim Papp, Robert Bissonnette, Melinda Gooderham, Steven Feldman, Lars Iversen, Jennifer Soung, Zoe Draelos, Carla Mamolo, Vivek Purohit, Cunshan Wang, William Ports
Figure S1. Change from baseline in DLQI through Week 16. Table S1. Serious adverse events by treatment group. Table S2. Number and percent of plasma tofacitinib concentration samples (pre-dose and post-dose) by concentration range – available data mild/moderate - post hoc. Table S3. Summary of plasma tofacitinib pharmacokinetic parameters - available data at week 4 - mild/moderate - post hoc. (DOCX 238 kb)

Funding

Pfizer

History